Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.59 |
| ▸ | ALB | P02768 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | BLM | P54132 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | MTOR | P42345 | 2/20 | 0.34 |
| ▸ | DNMT1 | P26358 | 2/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.34 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.34 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.34 |
| ▸ | GMNN | O75496 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | THPO | P40225 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | HBB | P68871 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5952944 | 1.00 | LMNA (0.59) | LMNAALBALDH1A1BLMPOLB | |
| Elvucitabine SCHEMBL1649928 | 0.84 | ALB (0.55) | LMNAALBALDH1A1BLMPOLB | |
| Elvucitabine SCHEMBL3298257 | 0.84 | ALB (0.55) | LMNAALBALDH1A1BLMPOLB | |
| SCHEMBL30667453 | 0.84 | LMNA (0.46) | LMNAALBALDH1A1BLMPOLB | |
| Dexelvucitabine SCHEMBL599014 | 0.84 | ALB (0.55) | LMNAALBALDH1A1BLMPOLB | |
| SCHEMBL4277774 | 0.83 | ALDH1A1 (0.57) | LMNAALBALDH1A1BLMPOLB | |
| SCHEMBL9665842 | 0.81 | ALDH1A1 (0.45) | LMNAALBALDH1A1BLMPOLB | |
| SCHEMBL5075702 | 0.80 | LMNA (0.43) | LMNAALBALDH1A1BLMPOLB | |
| SCHEMBL9856521 | 0.77 | POLG (0.50) | POLB | |
| SCHEMBL5821 | 0.76 | LMNA (0.55) | LMNAALBALDH1A1BLMPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150150893-A1 | ANDROGRAPHOLIDE ANALOGS AND THEIR USE FOR MEDICATION | LIAONING LIFENG SCIENT & TECHNOLOGY DEV COMPANY LTD (CN) | 2015-06-04 | — | — | US | claimed |
| US-6599887-B2 | Aids, herpes virus | CHIMERIX, INC. | 2003-07-29 | — | — | US | claimed |
| US-6448392-B1 | LIPID, ESPECIALLY PHOSPHOLIPID, DERIVATIVES OF MODIFIED ANTIVIRAL NUCLEOSIDE ANALOGUES CAN BE INTEGRATED INTO STRUCTURE OF LIPOSOMES, FORMING STABLE LIPOSOMAL COMPLEX, DELIVER GREATER AMOUNTS OF DRUGS TO CELLS WITH LESS TOXICITY | CHIMERIX, INC. | 2002-09-10 | — | — | US | claimed |
| EP-0409227-A2 | Pyrimidine nucleosides, their preparation and pharmaceutical preparations | MATTHES, Eckart, Dr. (DE) | 1991-01-23 | — | — | EP | claimed |
| US-20150150893-A1 | ANDROGRAPHOLIDE ANALOGS AND THEIR USE FOR MEDICATION | LIAONING LIFENG SCIENT & TECHNOLOGY DEV COMPANY LTD (CN) | 2015-06-04 | — | — | US | disclosed |
| US-20080249066-A1 | ANTIVIRAL COMPOUNDS AND COMPOSITIONS | ARDEA BIOSCIENCES, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| WO-2008118879-A2 | ANTIVIRAL COMPOSITIONS COMPRISING 2 COMPOUNDS | ARDEA BIOSCIENCES, INC. (US) | 2008-10-02 | — | — | WO | disclosed |
| US-20060217345-A1 | Beta-L-nucleosides and use thereof as pharmaceutical agents for the treatment of viral diseases | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2006-09-28 | — | — | US | disclosed |
| US-6448392-B1 | LIPID, ESPECIALLY PHOSPHOLIPID, DERIVATIVES OF MODIFIED ANTIVIRAL NUCLEOSIDE ANALOGUES CAN BE INTEGRATED INTO STRUCTURE OF LIPOSOMES, FORMING STABLE LIPOSOMAL COMPLEX, DELIVER GREATER AMOUNTS OF DRUGS TO CELLS WITH LESS TOXICITY | CHIMERIX, INC. | 2002-09-10 | — | — | US | disclosed |
| EP-0409227-A2 | Pyrimidine nucleosides, their preparation and pharmaceutical preparations | MATTHES, Eckart, Dr. (DE) | 1991-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249066-A1 | ANTIVIRAL COMPOUNDS AND COMPOSITIONS | PNP, TYMP, MTAP | LMNA 1063/4885ALB 1242/4885ALDH1A1 2654/4885 |
| US-20060217345-A1 | Beta-L-nucleosides and use thereof as pharmaceutical agents for the treatment of viral diseases | NTPCR, PNP, TYMP | LMNA 158/4885ALB 4041/4885ALDH1A1 211/4885 |
| US-20150150893-A1 | ANDROGRAPHOLIDE ANALOGS AND THEIR USE FOR MEDICATION | CYP11B1, CYP51A1, CYP11B2 | LMNA 2583/4885ALB 4628/4885ALDH1A1 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.